Kurayev Anna, Ashkar Huda, Saraiya Ami, Gottlieb Alice B
J Drugs Dermatol. 2016 Aug 1;15(8):1017-22.
Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterized by significant morbidity. The clinical course of HS ranges from relatively mild cases characterized by recurrent tender, subcutaneous, inflammatory nodules to severe cases demonstrating painful, deep dermal abscesses, fibrosis, draining sinuses, and hypertrophic scars. Conventional treatment options for management of HS include topical and systemic antibiotics, antiandrogens, fumarates, biguanides, retinoids, immunosuppressive drugs, laser and phototherapy, and surgical excision. Given its association with pro-inflammatory cytokines, there has been interest in the use of novel biological agents. Recently, available treatment options have expanded to include tumor necrosis factor alpha inhibitors (TNF-ai), interleukin-1 inhibitors (IL-1i), and interleukin-12/23 inhibitors (IL-12/23i), but the management of HS is still very challenging. In this review, the authors will discuss new therapies for HS.
J Drugs Dermatol. 2016;15(8):1017-1022.
化脓性汗腺炎（HS）是一种具有显著发病率的慢性炎症性疾病。HS的临床病程范围较广，从以反复出现的压痛性皮下炎性结节为特征的相对轻症病例，到表现为疼痛性深部真皮脓肿、纤维化、引流窦道和肥厚性瘢痕的重症病例。HS的传统治疗方法包括局部和全身使用抗生素、抗雄激素药物、富马酸盐、双胍类药物、维甲酸类药物、免疫抑制药物、激光和光疗以及手术切除。鉴于其与促炎细胞因子有关联，人们对使用新型生物制剂产生了兴趣。最近，可用的治疗选择已扩展到包括肿瘤坏死因子α抑制剂（TNF-ai）、白细胞介素-1抑制剂（IL-1i）和白细胞介素-12/23抑制剂（IL-12/23i），但HS的治疗仍然非常具有挑战性。在这篇综述中，作者将讨论HS的新疗法。
《皮肤药物学杂志》。2016年；15（8）：1017 - 1022。
